MARKET

FMTX

FMTX

Forma Therapeutics Holdings, Inc.,
NASDAQ

Real-time Quotes | Nasdaq Last Sale

45.29
+1.41
+3.21%
After Hours: 45.29 0 0.00% 16:29 09/18 EDT
OPEN
44.17
PREV CLOSE
43.88
HIGH
47.66
LOW
44.03
VOLUME
2.74M
TURNOVER
--
52 WEEK HIGH
50.00
52 WEEK LOW
31.45
MARKET CAP
1.67B
P/E (TTM)
-23.3357
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average FMTX stock price target is 56.25 with a high estimate of 64.00 and a low estimate of 53.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FMTX
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for patients with rare hematologic diseases and cancers. Its pipeline consists of seven product candidates, two of which it is pursuing as core product candidates for development: FT-4202 for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Its other product candidate includes FT-2102 (Olutasidenib), FT-8225, FT-4101, CC-95775 and BI-1701963. FT-4202 is an oral, once-daily, potentially disease-modifying therapy. FT-4202 is a potent activator of pyruvate kinase-R (PKR), designed to improve RBC metabolism, function and survival, and potentially resulting in both increased hemoglobin levels and reduced VOCs. FT-7051, is a potent and selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Forma Therapeutics Holdings Inc stock information, including NASDAQ:FMTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FMTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FMTX stock methods without spending real money on the virtual paper trading platform.